The potential for proarrhythmic responses to the class IC sodium channel-blocking Octet encainide and Ilecatnide has out been well described in young patients. Therefore, data were retrospectively c llected from 36 institutions regarding 579 young patients who were administered encaiddr, or 0eenlnide for treatment at m . preset lricnlar tachyeardias (eneainide 06 poll ®eminide 369 patienfr) or ventricular arrhyfhmias (encainide 21 patients, fiecumide 103 patients) to assess the frequency of proarrhythmia, cardiac arrest and death during therapy (adverse ecenls), The two drugs were stroller in regard to efficacy (&ecatnlde 71,1%, encainide $9 .8%) and rate of proarrhythndc responses (flecalnide 7.4% ; encainide 7.5'9x). However, patients receiving eneainide more frequently experien:^d .cardiac arrest (encainide 7.5% vs . llecalnide 2 .3%, p < 0.051 or tici awing treatment lencainide 7,5% vs . flecainide 2 .1% . p < 0.05).
Detailed data were provided for 44 patients experiencing one or rare adverse events. Patient age, previous drug trials, rm. comitant therapy and days of Inpatient monitoring wen similar Encainide and flecainide are class IC anliarrhythmie agents that have been shown to be highly effective in the treatment of ventricular and supraventricular arrhythmias II-Ibl . However, the potential for adverse effects attributable to proarrhythmic responses is well recognized for both drugs, among patients receiving the drugs for either ventricular (11) (12) (13) (14) (15) (16) (17) or supraventricatar (6,9,10 .17,18) arehythmias. Spo. radic adverse events have also been reported among young patients receiving these drugs (19--27) , but the overall extent of these effects in such patients has remained uncertain because of the relatively small numbers within individual series.
The Pediatric Electrophysiology Group reviewed the combined experiences of flecainide and encainide administration in young patients among 36 Chirngo . 1lflnms and Chrrrlesrott, Sann1 Cnrnfhtd for patients receiving encainide or flecatnide. However, echocardiogrephic left ventricular shortening before treatment was lower among patients receiving encainide (0.23 ± 0.09) than among those recehhlg Mainlde (0.34 t 0.06, p < 0.05). Plasma drug roarentratimrs were rarely elevated . Cardiac arrest (12 patients) and deaths (13 patients) occurred predmlnantly among patients with underlying heart disease, particularly among patients receiv lug fleratnide for supraventrkvlar mrhyrardla (0.3% vs. 0.3%, p < 0.001).
Fifteen patients with an ostensibly normal heart and normal ventricular function experienced proarrhythmia during treatment for supraventrkular tachycardin, Eat only 3 of the 15 had a cardiac arrest or died. The relatively high incidence of adverse events should be considered when contemplating treatment with encainide or fkcainide, particularly among patients with undertying heart disease .
fj Am Cull Crvdiol 1991;18:356-65) goals of the study were to ascertain among young patients the overall incidence of documented proarrhythmia and adverse events such as cardiac arrest or sudden death possibly attributable to proarrhythmia . An effort was also made to characterize the specific types of adverse events and the clinical settings in which they occurred to determine whether adverse events could be attributed to underlying heart disease, encessivc drug do~ges, concomitant therapy, ventricular dysfunction or severity of the underlying arInitial questionnaires. Data were collected by distributing two questionnaires among members of the Pediatric Electrophysiology Group . The initial questionnaire, prepared in March !989, asked physicians to summarize their use of flccainide and encainide in young patients. This questionnaire was intentionally streamlined to maximize participation among the memhers of the group and asked only for the total number of patients treated, the number in whom each drug was considered effective, the number with underlying heart disease and the number of patients experiencing each of three types of adverse events during therapy : proarrhythrhythmia-Methods mia, cardiac arrest and death . Subtotals were provided fur both encainide and flecainide and for all supraventricular tachycardias and all ventricular arrhythmias .
Definition. Cardiac arrest was defined as sudden hemodynamic collapse (pulselessness and apnea) recuiring cardiopulmonary resuscitation or cardioversion with documented ventricular fibrillation. Total deaths during therapy included all deaths regardless of cause or duration of therapy at the time of death. Sudden death referred only to death occurring during therapy under circumstances suggestive of arrhythmia and not clearly attributable to other causes. Prourrhythnria (whether or not asstetated with either cardiac arrest or death) required ECG documentation of a new arrhythmia or worsening of an existing arrhythmia by the criteria of velebit et al. (28), usually during the lit 2 months of therapy . On the initial questionnaire, proarrhythmia could thus occur independently or in association with either cardiac arrest or death .
Follow-up questionnaire . After the initial questionnaires were collected, a follow-up questionnaire was distributed to obtain detailed information regarding each patient who experienced an adverse event . This detailed questionnaire was completed only for those patients experiencing an adverse event ; comparable data were not collected for those patients not experiencing an adverse event during effective treatment or in whom treatment was discontinued because of inefficacy. Particular emphasis was placed on determining whether these events could be attributed to the type of arrhythmia being treated, underlying heart disease or abnormal ventricular function, excessive dosing or concomitant therapies being administered at the time of an adverse event . Data obtained thus included age, weight, height, body surface area, anatomic and functional cardiac diagnoses (including previous cardiac surgery or suspected cardiomyopathy) and a qualitative (and, when available, quantitative) estimate of systemic ventricular function before treatment . All known arrhythmias before treatment were listed, and data on per manent pacemaker implantation and indications for pacing were provided . The indications for therapy with encainide or flecainide were also stated, including data on all antiarrhythmic drugs previously administered. Dosing information included the frequency of administration, days of inpatient monitoring, apparent efficacy of treatment and any other cardiovascular drugs being administered concurrently . Finally, the circumstances of the adverse event were described, including duration of treatment, plasma drug concentrations closest to the date of the adverse event, rhythm documentation when available, treatment provided in response to the event and the outcome of treatment.
Arrhythmia classification . A uniform classification was utilized for rhythm diagnoses . Sapeavenrrirular rachycardias included all reciprocating tachycardias, including atrioventricular (AV) reciprocating tachycardia, reentry within the AV node and the permanent form of junetional reciprocating tachycardia; primary atrial tachycardias, including atria) ectopic tachycardia, atria) flutter or intraatrial reentry 
Results
Initial Questionnaire (Table 1) The initial questionnaire was completed by 36 investigators in the United States, Canada, Great Britain and The Netherlands who had administered to 579 young patients either flecainide (472 patients) or encainide (107 patients), mostly for treatment of supraventricular ventricular nrrhythmias (flecainide 70% . encainide 00%v) . Congenital heart disease was present in 137 of these 579 patients (108 receiving flecainide vs . 29 receiving encainide, p = NS) . Data on age, gender and specific types of underlying heart disease were not available for all 579 patients . Both drugs were highly effective. Overall efficacy was slightly greater for flecainide than for encainide (71 .4% vs. 59.5%, p < 0.05), primarily reflecting the slightly greater efficacy of flecainide for supraventricular taehyeardias (70% vs . 57%, p c 0.05) ; venIricular arrhylhmias were similarly responsive to each drug .
Overall proarrhythmia . Overall proarrhythmia was frequent (7 .4%) and was similar for both drugs (encainide 7 .5% vs. flecainide 7 .4%, p = NS) . There was no difference between the mean rate of proarrhythmia in patients with supraventricular tachycardia (7 .7%) and that in patients with ventricular arrhythmia (6.4%, p = NS) . Likewise, proorrhythmia due to each drug was comparable among patients with supraventricular tachycardia (encainide 6 .9% vs . flecainide 7 .9%), and those with ventricular arrhythmia (encainide 9 .5% vs. flecainide 5 .8%, p = NS).
Overall cardiac arrests and deaths . In contrast to overall proarrhythmia, the proportion of cardiac arrests and total deaths was greater among patients receiving encainide than among those receiving flecainide (cardiac arrests 7 .5% vs . 2 .79( deaths 7 .5% vs . 2 .1% ; p < 0.05 for both) . This Overall adverse events. From the initial questionnaire, up to 80 adverse events were reported . However, the questionnaire design did not allow determination of the total patients affected, since an individual could experience any type of adverse event individually orcould experience a single event fulfilling the criteria for sudden death, cardiac arrest and proarrhythmia . Thus, the follow-up questionnaire allowed an indirect determination of the overall number of patients affected .
Underlying heart disease, Proarrhythmia was similarly common among patients with congenital heart disease and those with a structurally normal heart 110°)3 vs . 6.1% . p = NS) whether they were receiving flecainide 112,5% with heart disease vs . 7 .3% without, p = NS) or encainide (3 .67°W ith heart disease vs . 13 .5% without, p = NS) . However, the proportion of cardiac arrests and total deaths during flecainide treatment for supravcotroculartwhycarda was . far greater among patients with congenital heart disease [cardiac arrests 8,3%p vs . 0.3% . P e 0 .001 ; deaths 6 .8%p vs. 0 .3%. p < 0 .001) . A similar relation between deaths or cardiac arrests and congenital heart disease could not be demonstrated for either drug in the treatment of ventricular arrhythmia, Follow-Up Qaeslionnaire : Adverse Events (Tables 2 to 51 From the 36 institutions responding to the initial questionnaire, follow-up data were provided by 14 of 17 institutions reporting one Or more patients who experienced an adverse event. Thus, individual data were made available for 44 of the approximately 50 patients who experienced one or more of the adverse events (12 receiving encainide, 32 receiving flecainide, Table 2 ) . Those experiencing adverse events during treatmcm with encainide or flecainidc were similar in regard to age, duration of therapy, the number of prior antiarrhythmic drugs and the number of coadministered cardiovascular medications, However, echocardiographic left ventricular shortening fraction (before treatment) was significantly lower among those patients given encainide (D.23 m 0.09 vs . 0 .34 t 0 .06, p < 0.05) .
Association with suspected risk factors. Multivariate or univariate analyses to identify individual risk factors were not feasible, because the questionnaire design provided detailed individual information only for those patients who experienced an adverse event, However, the distribution of several suspected risk factors could be examieod among these patients.
Type of arrhylhmia and high saw low risk (Table 3) .
Among the 44 patients experiencing an adverse event, 34 were being treated exclusively for supraventricular tachycardia (10 receiving encainide, 24 receiving flecainide, with the remainder being treated for ventricular arrhythmia alone (I receiving encainide, 5 receiving flecainide) or in combina- 'Additional arrnythmies leeen(O, within eh+ mdao-earioiae 1AVl node, two pariepts : Camplek eemrt.,c r temp, adivity . Ihrre pahedh'. sparllana e0s sentrietlr tachycardia . one patmnll. tone parcel xith cengerital long QT syndrome. AVNRT -reenlrv widen the 9V node. AVRT = AV reciprocating ulehyenPoia loll annaolromrF : EPS = decuuphysiuugic study . PIRT = permanent junctional reciprocating tachycardia, lion with supraventricular tachycardia ( I receiving encainide, 3 receiving flecai side) . Of the 34 patients being treated for only supraventricular tachycardia 17 were presumed to be at high risk because of associated heart disease or poor hemodynamic state, whereas 16 patients were at presumed low risk because of an ostensibly normal heart and nonlethal arrhythmia (t patient was considered to be at undetermined risk) .
Four of six patients with exclusively ventricular arrhythmia and two of four patients with multiple atrial and ventricular arrhythmias were believed to be at definite high risk for sudden death on the basis of long QT syndrome (one patient) or previous cardiac arrest m syncope with documented ventricular tachycardia (spontaneous to three patients . induced at etectrophysiutogie study in four) . Four other patients were presumed to be at high risk for sudden death because of the presence of complex ventricular ectopic Ventricular dysfunction and underlying heart disease ('table 4). Among the 44 patients who experienced an adverse event . 29 had underlying congenital (excluding a manifest pre-excitation syndrome) or funetiana! heart disease (19 of 32 receiving neeainide, 10 of 12 receiving encainidel . This group included 14 patients who had undergone a previous operation for congenital heart disease or accessory AV connections (4 receivjng encainide, 10 receiving flecainidel. There was also objective or subjective evidence of systemic ventricular dysfunction in 14 of the 29 patients . including 4 whose dysfunction was attributed to c%trunic tachycardia. Fifteen of the 44 patients had an -'ostensibly normal' heart with no identifiable functional abnormality (other than the primary arrhythmia) .
Dosing and plasma concentration. All patients were hospitalized during iniliatic-0 of treatment for an average of 6 .4 a 3 .7 days (range 0 to 21) . Doses at the time of the adverse events were generally within previously recommended ranges for young patients: o5 .7 mg/kg per day Is 120 mglm'' per day) for 11 of 12 patients receiving cncomide and <6 mgfkg per day (<200 mglm e per day) for 27 of 32 patients receiving fleeainide (20, (24) (25) (26) . The maximal encainide dose reported was 6 .7 mglkg per day (175 mg/m2 per day) . ,rd the maximal Becainide dose reported was 12 .) mglkg perday (332 mbar' per day) . No differences were evident between flecatnide dose and the type of adverse event (Fig. 1) .
Flecainide plasma concentrations were available from 27 of the 32 patients experiencing an adverse event (mean 550 320 ngml) . and were elevated C>1,000 nglmi) in only 2 patients 1Fig . 1). Flecainide concentrations at the dual dose were no different among 10 patients experiencing an adverse event after the 1st 2 months of therapy (590 ± 400 ng/mll compared with those experiencing an early adverse event (520 x 240 nglml) . Concentrations were likewise similar among patients experiencing proarrhythmia only (414 *_ 267 rpiml), cardiac arrest (490 no 275 nglml) and sudden death (620 ± 160 ngiml . excluding a single markedly elevated result of 1 .710 nglml( . Plasma concentrations for encainide and the active metabolites were available in only 3 of I I patients ; none of these concentrations were elevated (cor- recting for extent of metabolism to 0-desmethyl encainide) (29) . Concomitant therapy (Table 5) . Twenty-five of the 44 patients experiencing an adverse event were receiving one or more cardiovascular medications in addition to encainide (9 patients) or flecainide (15 patients) . Digoxin was the most commonly coadministered medication (18 patients) . The coadministration of other drugs was not examined among patients who did not have an adverse event .
Early versus Late adve :-ne events. An adverse event occurred within the 1st 2 months (loran 9 .9 days) in 31 of the 44 patients (22 receiving flecainide, 9 receiving encainide), including 2 patients who developed incessant ventricular lachycardia with intravenous flecainide administration . Twenry-two patients experienced on adverse event during inpatient monitoring, including 10 who experienced cardiac arrest (9 patients) or died (I patient) . Nine other patients experienced apparent proarrhythmia (two patients), cardiac arrest (one patient) or death (six patients) soon after being discharged on treatment .
Death (six patients) or cardiac arrest (three patients) occurred late (>2 months) after the start oftreatment in nine patients . Although only two of these nine patients were at definite high risk, seven had underlying congenital heart disease that had been surgically treated in six . All seven patients were being treated for atria) flutter either alone (four patients) or in combination with ventricular arrhythmia (three patients), and all had a ventricular demand pacemaker before treatment . One additional patient with hypertrophic cardiomyopathy died late while receiving flecainide, and one with an "ostensibly normal" heart had a late cardiac arrest . Thus, eight of nine late-occurring lethal or potentially lethal adverse events occurred in patients at either definite or presumed high risk . Four other patients experienced an adverse event after the Ist 2 months of therapy that their reporting physician considered to be suggestive of proarrhythmia . This group included one patient who developed new incessant ventricular tachycardia (without cardiac arrest) 85 days after the start of flecainide therapy; tachycardia did not recur after the dose was decreased . The remaining three patients experienced either marked exacerbation of AV reciprocating tachycardia or incessant supraventricular tachycardia.
Type of adverse event and apparent risk (Tables 6 and 7 ). Patients who died or were successfully resuscitated from cardiac arrest are listed in Table 6 . Death was sudden with no other identifiable cause in 12 of 13 patients and was thus presumed to be due to arrhythmia . The remaining patient died of progressive congestive heart failure during treatment with encainide rather than from an arrhythmia . Three of the patients who died suddenly or experienced cardiac arrest within the 1st 2 months of treatment were at known high risk as characterized earlier; two other patients known to be at high risk died or survived cardiac arrest late (407 and 387 days, respectively). Sixteen of the remaining 20 deaths or cardiac arrests occurred in patients presumed to be at high risk (or undefined by the reporting investigator) . Thus, patients either known or presumed to be at high risk accounted for 21 of 25 lethal events possibly related to proarrhythmia.
Only 4 of the 25 patients experiencing cardiac arrest or death had no underlying heart disease and were presumed to be at low risk during, treatment for supraventricular tachycandies (Table 6 ) . These events were clearly related to treatment in at least three of these four patients, all ofwhom were being treated for supraventricular tachycardia . One of these three patients died 22 days after beginning treatment with encainide and two patients experienced cardiac arrest during intravenous flecainide administration (one of whom later developed incessant supraventricular lachycardia during oral flecainide therapy). A fourth patient had a cardiac arrest 23 months after beginning flecainide therapy (for tachycedia due to reentry within the AV node) despite a low therapeutic flecainide concentration (352 nglml) at a dose of 6 .5 mglkg per day (249 mglm 2 per day). Despite this late occurrence, the cardiac arrest was attributed to flecainide, and the patient experienced no subsequent cardiac arrest over 20 months after flecainide was discontinued.
Twelve of18 patients who experienced proarrhythmia not resulting in cardiac arrest or death developed incessant sapraventricular lachycardia (wide or narrow QRS complex) during flecainide treatment for paroxysmal AV reciprocating lachycardia (Table 7) . Four other patients developed new ventricular tachycardias during treatment for atrial flutter (two patients), permanent junctional reciprocating tachycardia (one patient), or reentry within the AV node (one patient) . One patient was considered to have proarrhythmia at electrophysiologic study and another developed high grade AV block and bradycardia during encainide Table 6 .
known or suspected high risk of sudden death . Nevertheless, similarly severe adverse events occasionally occurred in patients presumed to be at low risk on the basis of nonlethal underlying arrhythmia and an "ostensibly normal" heart . Furthermore, proarrhythmia not resulting in cardiac arrest or death occurred frequently even in such low risk patients . Proarrbythmta . Proarrhythmia could not be attributed to excessive dosage or plasma concentrations in the majority of adverse events, Three of the patients with an "ostensibly normal" heart with severe hemudynamic compromise (classified under cardiac arrest) were receiving intravenous therapy for AV reciprocating taehyeardia, one of whom also later experienced proarrhythrnia (incessant AV reciprocating tachyeardia) during oral therapy (Table 7) . Several items of potential interest in predicting potential risk for proarrhythmia in individual patients were not examined, including the potential role of changes in QRS duration, exercise testing or follow-up etectrophysiologic testing (12,15,36) .
Limitations of the study. This study suffers from several limitations because of its retrospective nature . Patients were not randomized to receive flecainide or encainide, limiting any direct comparison of these two drugs with respect to either efficacy or potential risk. Indeed-encainide appeared to be reserved predominantly for patients with impaired ventri,alar dysfunction, probably accounting far at least part of the higher incidence of cardiac arrest and death associated with its use . Furthermore, 35 of the 36 participating investigators reported using flecainide whereas only 15 investigators had used encainide, Presumably, patients who were administered encainide rather than flecaimde at these instirations because of ventricular dysfunction might have received alteraative treatment at other institutions, possibly with similarly adverse outcomes . The lack of a comparable prospective or histoncal control group receiving either no The use of two questionnaires also presented certain limitations to the study as well as possible strengths. The goal of minimizing the information collected in the initial questionnaire in order to maximize the number of institutions willing to contribute their experience appeared to be successful . A high rate of participation was considered essential to fulfill the primary objective of assessing the overall extent of adverse events during encainide and flecainide administration. The use of the second detailed questionnaire provided a qualitative alternative to examine the spectrum of patients in whom both lethal and nonlethal adverse events had been observed. Although the statistical significance of these observations is tentative, the simple 2 x 2 comparisons help support the general finding that proar• rhythmic was common among all groups but cardiac arrest and sudden death usually occurred in patients with underlying heart disease .
Finally, a concise defi,eilion of peoarrhythmia is itself problematic in the retrospective study we report. While limiting adverse events attributable to proarrhythmia to those occurring within the 1st 2 months of therapy has been advocated (28), data from CAST (13,31) demonstrated a continued decline in survival in the encainide and flecainide treatment group compared with placebo well after the Ist 2 months of treatment . Thus, adverse events that occurred after 2 months under circumstances highly suggestive of true proarrhythmic responses were included in this report. Nevertheless, the proportion of cardiac arrests or sudden death, during or after the tat 2 months that truly represent proarrhythmia responses to therapy remains undetermined. 'Nol necessarily aanbmed to prvurhythma . responses, tyouled data from multiple it-.sligaturs . VF = ventricuLa, fibrillation; other abbreviation as in Tables 6 and 7 .
Comparison with previous reports of proarrhyrhmia (Tables 8 and 9). Previcus studies (8, 11, 12, (14) (15) (16) 32, 33) identified proarrhythmia in 7% to 16% of patients receiving encainide and 3% to 16% receiving flecainide . These were predominantly studies of patients receiving treatment for ventricular arrhyihmias . These and other studies were pooled by Morganroth and Horowitz (15, 16) to provide sufficient numbers (1,245 patients receiving encainide . 1 .330 receiving flecainide) to identify risk factors for proarrhythmia, including presence of structural heart disease (including valvular, atherosclerotic or cardiomyopathic processes) and sustained versus nonsustained ventricular tachycardia .
Several reports (5-7,10,34) in adults have suggested that patients with supmventricular arrhythmia or nonsustained ventricular laehycardia and an otherwise normal heart may be at very low risk for proarrhythmia. The current study suggests that the infrequency of proarrhythmia in such patient groups may largely reflect, rather than actual protection from proaeThythmia, the relative infrequency with which encainide or flecainide has been administered for 'Contributed to the present study . Abbreviations as in Tables 6 and 7 . FISH ET AL. 363 ENCAINIDE AND FLECAINIDE IN YOUNG PATIENTS these arrhyihmias compared with more serious ventricular arrhythrLias . Instead, this study supports Morganroth's observation (16) that the severity of proarrhythmic responses was more closely related to risk factors than to overall incidence of ptoarrhythmia . Furthermore, as in Morganroth's report (16) , the risk of adverse responses appeared to vary more among patients receiving flecainide than among those receiving encainide, although direct comparison of the two drugs is tentative .
Clinical implications, Despite the justified concerns generated by the CAST report and the present report, several questions remain unanswered . The extent to which these results apply strictly to encainide and flecainide remains undetermined . For example, patients in the present study with atria! flutter after surgery for congenital heart disease had generally been treated unsuccessfully with multiple medical regimens before receiving encainide or flecainide . Yet both encainide and flecainide were quite effective in this drug-rfractory group . A less effective antiarrhylhmie agent with a similar tendency to proarrhythmin might have pre- (9) r l AF II seated even greater risk to these patients because failure to successfully treat atrial flutter has been associated with mortality in such patients (35) . Such a possibility is supported by mela-analysis of multiple prospeclive placebocontrolled tnals (36) that demonstrated an overall increase in mortality among adult patients treated with quinidine far prim fibrillation.
The infrequency of lethal events in putientr with a strucrurally normal heart and normal ventriadarfunrtion being treated for supravenlricular tachycardias may support the view of a low risk patient profile . That is, although proar .
rhythmia was common among all risk groups, cardiac arrest and death were uncommon among patients with an otherwise normal heart receiving flteainidc in, supravcntricular tatdnycardia . Only two such "normal" patients in the entire study experienced a lethal event if only those receiving oral therapy are considered, This observation supports the findings of Perry et al . (26) . whose )rodents were included in the present report.
The potential role of colnhmntion drag regirnerls in lire patients who had an adverse event remains undetermined .
The frequent use of other drugs in combination with flecainide and encainide supports the drug-refractory nature of these patients' arrhythmias . Because both the resistance to therapy and the risk of adverse events during therapy may be related to underlying heart disease, it would be extremely difficult to assess any potential incremental risk ofcombination therapy without prospective randomized analysis .
Perhaps a more difficult issue is whether long-term administration of these drugs imparts a cumulative risk of prtmrr)tyihmiu or deurk in either low risk or high risk patients who are apparently tolerating the drugs well, The long-term follow-up data were not sufficient to assess any potential long-term cumulative risk . While the late cardiac arrest in a single patient with lachycardia due to reentry within the AV node is worrisome, this was an otherwise atypical event in this large study population . In general, having a supraventricular tachycardia and an ostensibly normal heart would seem to impart a lower risk for serious adverse events, but may not exclude the potential for late proarrhythmic responses during treatment .
CRnclusinns . The frequency of proarrhythmia, cardiac arrest and death in this study reinforces the need to continually reexamine the indications for initiating and continuing anliarrbythmic drug treatment (33) . In the present study, suppression of asymptomatic ventricular ectopic activity or ventricular tachycardia induced only at electrophysiologic study was cited as an indication for therapy in eight patients who subsequently experienced an adverse event, possibly attributable to proarrhylhmia . As in adults with iechemic heart disease, the merit of treating certain asymptomatic ventricular arrhythmias in an effort to prevent sudden death among young patients will require further scrutiny . Ultimately, prospective randomly assigned trials in stratified patient groups may be necessary to define risks and benefits of various antiarrhythmic therapies . 
